The OLYMPIA trial (NCT02032823) found that adjuvant olaparib for patients with BRCA1- or BRCA2-Mutated BC was associated with significantly longer survival free of invasive or distant disease than was placebo [61]. Here, BRCA2 is linked to breast cancer.